Cover Image
市場調查報告書

美國的個人化癌症基因定序市場

US Personalized Cancer Genome Sequencing Market Outlook 2018

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 250711
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
美國的個人化癌症基因定序市場 US Personalized Cancer Genome Sequencing Market Outlook 2018
出版日期: 2014年03月01日 內容資訊: 英文 65 Pages
簡介

全基因定序技術過去10年以空前的速度發展。生物資訊學為基礎的資料分析用定序平台,與個人化醫療的適用等動向並進,從特定基因定序到全基因定序技術進步得到急速推進。還有,全基因定序也成為癌症治療的新突破。透過新手法的開發,基因資料可適用於癌症的個人化醫療,那使全基因定序的成本大幅度降低。

本報告提供美國的個人化癌症基因定序市場中、全基因定序的領域相關分析、美國的癌症得病率、發病率的狀態(過去4年的實際成果值與今後五年的預測值),及潛在、明示的市場規模預測、相關法規趨勢、應克服的課題、相關企業簡介的調查評估,並將結果概述為以下內容。

第1章 分析師的見解

第2章 分析方法

第3章 基因定序:概要

第4章 癌症患者的人口統計

  • 得病率、發病率、死亡率(總計9年份)
  • 發病率高的州
  • 發病率高的癌症的種類
    • 男性的癌症發病率
    • 女性的癌症發病率
    • 各年齡層

第5章 美國的個人化癌症全基因序列:潛在的市場

第6章 美國的個人化癌症全基因序列:現在及未來市場分析

第7章 法規相關考察

  • 臨床實驗室改進法案(CLIA)的認證
  • 美國病理學會(CAP)的認證

第8章 市場阻礙因素

第8章 競爭企業的評估

  • Illumina
    • 產業概要
    • 主要資料
    • 優勢、弱點
  • Complete Genomics
  • Beckman Coulter Genomics
  • Expression Analysis
  • EdgeBio
  • Foundation Medicine
  • SeqWright
  • Ambry Genetics
  • BGI Americas Corporation
  • Cofactor Genomics

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The whole genome sequencing technology, over the past decade, has developed at an unprecedented rate. There has been a rapid progression from targeted gene sequencing to targeted whole genome sequencing coupled with bioinformatics based sequencing platforms to analyze the data and thereby impart personalized treatment to individuals. The Whole Genome Sequencing has proved to be a key to new breakthrough in fighting against cancer. The explosion of genomic data into personalized treatment of cancer is due to the development of new methods, and the exponential decline in cost of whole genome sequencing.

Our report entitled “US Personalized Cancer Genome Sequencing Market Outlook 2018” entails detailed study of current and future cancer prevalence and incidences across US. In addition, it provides an insight about the leading states with cancer incidences. Also covered is age wise statistics for cancer and comprehensive figures for cancer in males and females. Further, we have provided potential states for whole genome sequencing to help market players gauge maximum opportunity for growth. Besides, the report also provides potential customer base and the market's growth potential for personalized cancer WGS till 2018.

The said advanced technology has potential to revolutionize the field of medicine. We have closely monitored the regulatory landscape related to sequencing which requires consideration of the authorities over genome based tests. It has been observed that whole genome sequencing services have been concurrently regulated by FDA, CDC and CMS. Further, we have also discussed the various constraints faced by the industry players with suitable suggestions to overcome them. Apart from this, a major hurdle is to persuade health insurers to reimburse for the cost of sequencing the genomes of individual.

The report analyzes the competitive landscape of the market by properly analyzing the business, services and activities of the companies such as Illumina, Complete Genomics, and Ambry Genetics. It also provides the competitive benchmarking, taking into account key information such as market value, revenues, risk score etc., along with the strengths and weaknesses of each player. Overall, the report is a complete source of knowledge and statistics for clients who want to get an in-depth understanding of the market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Genome Sequencing: An Introduction

4. Cancer Statistics by Demographics

  • 4.1. Prevalence, Incidences, and Mortality (2010-2018)
  • 4.2. Leading States by Incidence
  • 4.3. Leading Cancers by Incidence
    • 4.3.1. Male Cancer Incidences
    • 4.3.2. Female Cancer Incidences
    • 4.3.3. Age-Group

5. US Personalized Cancer WGS Potential Market to 2018

6. US Personalized Cancer WGS: Current and Future Market Analysis

7. Regulatory Insights

  • 7.1. Clinical Laboratory Improvement Amendments (CLIA) Accreditation
  • 7.2. CAP Accreditation

8. Market Constraints

9. Competitive Assessment

  • 9.1. Illumina
    • 9.1.1. Business Overview
    • 9.1.2. Key Information
    • 9.1.3. Strengths and Weaknesses
  • 9.2. Complete Genomics
    • 9.2.1. Business Overview
    • 9.2.2. Key Information
    • 9.2.3. Strengths and Weaknesses
  • 9.3. Beckman Coulter Genomics
    • 9.3.1. Business Overview
    • 9.3.2. Key Information
    • 9.3.3. Strengths and Weaknesses
  • 9.4. Expression Analysis
    • 9.4.1. Business Overview
    • 9.4.2. Key Information
    • 9.4.3. Strengths and Weaknesses
  • 9.5. EdgeBio
    • 9.5.1. Business Overview
    • 9.5.2. Key Information
    • 9.5.3. Strengths and Weaknesses
  • 9.6. Foundation Medicine
    • 9.6.1. Business Overview
    • 9.6.2. Key Information
    • 9.6.3. Strengths and Weaknesses
  • 9.7. SeqWright
    • 9.7.1. Business Overview
    • 9.7.2. Key Information
    • 9.7.3. Strengths and Weaknesses
  • 9.8. Ambry Genetics
    • 9.8.1. Business Overview
    • 9.8.2. Key Information
    • 9.8.3. Strengths and Weaknesses
  • 9.9. BGI Americas Corporation
    • 9.9.1. Business Overview
    • 9.9.2. Key Information
    • 9.9.3. Strengths and Weaknesses
  • 9.10. Cofactor Genomics
    • 9.10.1. Business Overview
    • 9.10.2. Key Information
    • 9.10.3. Strengths and Weaknesses

List of Figures:

  • Figure 3-1: Schematic Diagram of Sequencing used for Human Genome Project
  • Figure 3-2: Long-range Sequence Assembly in Whole Genome Shotgun Sequencing
  • Figure 4-1: Cancer Prevalence (Million), 2010-2018
  • Figure 4-2: Cancer Incidences (Million), 2010-2018
  • Figure 4-3: Cancer Mortality (‘000), 2010-2018
  • Figure 4-4: Incidences by Type of Cancer (%), 2014
  • Figure 4-5: Cancer Incidences by Age Group (%), 2010
  • Figure 5-1: Number of People earning > US$ 100K (2009-2012)
  • Figure 5-2: Potential Customers for Personalized Cancer WGS Market (Billion), 2013-2018
  • Figure 5-3: Potential Customers for Personalized Cancer WGS Market by Age-Group (%), 2014
  • Figure 5-4: Potential Market for Personalized Cancer WGS (Billion US$), 2013-2018
  • Figure 6-1: Tapped and Untapped Personalized Cancer WGS Market (%), 2014
  • Figure 6-2: Personalized Cancer WGS Market (Million US$), 2013-2018

List of Tables:

  • Table 4-1: Top Ten States with Highest Cancer Incidences (‘000), 2014
  • Table 4-2: Top Ten Cancer Incidences in Males (2014)
  • Table 4-3: Top Ten Cancer Incidences in Females (2014)
  • Table 5-1: Top Ten States with Households earning > US$ 100K (2012)
  • Table 5-2: Key Demographics and Potential Customers for Personalized Cancer WGS Market (2014)
  • Table 5-3: Potential States for Personalized Cancer Whole Genome Sequencing
  • Table 9-1: Illumina - Key information
  • Table 9-2: Complete Genomics - Key Information
  • Table 9-3: Beckman Coulter Genomics - Key Information
  • Table 9-4: Expression Analysis - Key Information
  • Table 9-5: Edge Bio - Key Information
  • Table 9-6: Foundation Medicine - Key Information
  • Table 9-7: SeqWright - Key Information
  • Table 9-8: Ambry Genetics - Key Information
  • Table 9-9: BGI Americas Corporation - Key Information
  • Table 9-10: Cofactor Genomics - Key Information
Back to Top